



RYBREVANT® + LAZCLUZE™ as a first treatment for advanced non-small cell lung cancer (NSCLC) with a certain *EGFR* mutation*

PROTECTING YOUR TIME, SO YOU CAN HELP HIM PROPEL HIS FUTURE

RYBREVANT® + LAZCLUZE™ protects your time by helping you live longer without your disease getting worse. At 23.7 months, half of the people receiving RYBREVANT® + LAZCLUZE™ did not have their cancer grow or spread, compared with 16.6 months for the current standard of care (osimertinib).[†]

*Mutations include exon 19 deletion or exon 21 L858R.

†Osimertinib is a preferred first treatment option for *EGFR* exon 19 deletion or exon 21 L858R mutations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (*EGFR*) gene(s):

- in combination with LAZCLUZE™ (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)

Your healthcare provider will perform a test to make sure that RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™ is right for you.

It is not known if RYBREVANT® or LAZCLUZE™ is safe and effective in children.

RYBREVANT® and LAZCLUZE™ may cause serious side effects, including: infusion-related reactions, lung problems, blood clot problems, skin problems, eye problems, and harm to your unborn baby.

Please read Important Safety Information throughout and on pages **14-17**.

Please read full [Prescribing Information](#) for RYBREVANT®.

Please read full [Prescribing Information](#) for LAZCLUZE™.



RYBREVANT® +
(amivantamab-vmjw)
Injection for IV Use | 350 mg/7 mL (50 mg/mL)



LAZCLUZE™
(lazertinib)
Tablets | 240 mg/80 mg

Table of Contents

About the Disease	<u>4</u>
How Treatment Works	<u>5</u>
Results From a Clinical Trial	<u>6</u>
Side Effects	<u>8</u>
Tips for Managing Side Effects	<u>9</u>
How RYBREVANT® + LAZCLUZE™ Are Given	<u>10</u>
Support & Savings	<u>13</u>

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT® as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT® and LAZCLUZE™ can harm your unborn baby.

Females who are able to become pregnant:

- o Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™.
- o You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
- o For patients receiving LAZCLUZE™: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- o Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT® or LAZCLUZE™.

Please read Important Safety Information throughout and on pages **14-17**.

2 Please read full [Prescribing Information](#) for RYBREVANT®. Please read full [Prescribing Information](#) for LAZCLUZE™.

Treatment Introduction

RYBREVANT® + LAZCLUZE™ is a first treatment for advanced non–small cell lung cancer (NSCLC) with a certain epidermal growth factor receptor (*EGFR*) mutation* that is proven to extend the time people live without cancer growing or spreading, compared with the current standard of care (osimertinib).

RYBREVANT® + LAZCLUZE™ is a treatment that is not chemotherapy.

If you have been prescribed **RYBREVANT® + LAZCLUZE™**, sign up for support and savings, including a Patient Starter Kit, at RYBREVANTwithMe.com.

*Mutations include exon 19 deletion or exon 21 L858R.

IMPORTANT SAFETY INFORMATION (cont'd)

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.

- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT®. It is not known if LAZCLUZE™ passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE™.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE™ may affect the way other medicines work, and other medicines may affect how LAZCLUZE™ works.

You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE™.



About the Disease



Lung cancer

Lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. As these cells grow, they form tumors. When cells from tumors spread to other parts of the body, it's called "advanced" or "metastatic" cancer.

In the US, the chance that a woman will develop lung cancer at some point in her life is 1 in 17. The chance that a man will is 1 in 16. These numbers include both people who smoke and those who don't smoke. Lung cancer can happen to anyone, regardless of smoking history.



Non-small cell lung cancer

The 2 most common types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

The difference between these types of lung cancer is how the cancer cells look under a microscope. There may be different treatments approved for use for each type.

NSCLC is the most common type of lung cancer. About 80% to 85% of all lung cancer cases are NSCLC.



Biomarker testing

Biomarker testing may help your doctor identify the appropriate treatment.

A biomarker can help show when your body is working normally or abnormally. This includes mutations in certain cells associated with advanced NSCLC.

A biomarker test identifies biomarkers by testing body tissue, blood, or other bodily fluids and can help your doctor determine which treatment is best for you. If you test positive for those biomarkers, there may be treatments available for your specific type of cancer. **If your tumor tests positive for EGFR exon 19 deletions or exon 21 L858R substitution mutations (sometimes referred to as "common"), RYBREVANT® + LAZCLUZE™ may be right for you.**



EGFR mutations

A protein called an epidermal growth factor receptor (EGFR) is found on both normal cells and cancer cells.

EGFR drives cells to survive and grow. **EGFR mutations may cause cancer cells to overgrow and spread to other parts of the body.**



EGFR exon 19 deletions/exon 21 L858R mutations (common)

There are 2 EGFR mutations that represent 80% to 90% of all EGFR mutations in NSCLC, so they're known as "common" EGFR mutations. These are called "exon 19 deletion" and "exon 21 L858R" mutations.

How Treatment Works

RYBREVANT® + LAZCLUZE™ are targeted treatments that work together to fight cancer without needing chemotherapy.

RYBREVANT® is a targeted antibody that works against EGFR mutations.* LAZCLUZE™ is an EGFR-targeted TKI (tyrosine kinase inhibitor). RYBREVANT® + LAZCLUZE™ work against cancer in different ways:

RYBREVANT® helps stop the activity cancer cells use to grow and spread from **outside** of the cancer cell.

RYBREVANT® also works with your immune system to help destroy the cancer.

LAZCLUZE™ helps stop the activity cancer cells use to grow and spread from **inside the** cancer cell.

*Antibodies are protective proteins that help detect harmful substances and diseases such as cancers. They are made naturally by your immune system and can also be man-made. Man-made antibodies used to treat cancer have a specific target on a cancer cell that they aim to find, attach to, and attack. RYBREVANT® is a man-made antibody.

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive RYBREVANT®?

- RYBREVANT® will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of infusion-related reactions.
- RYBREVANT® may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
- If your treatment with RYBREVANT® is given in combination with LAZCLUZE™ (lazertinib), you should take your dose of LAZCLUZE™ by mouth anytime before your infusion with RYBREVANT®.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.



Please read Important Safety Information throughout and on pages 14-17.

4 Please read full [Prescribing Information](#) for RYBREVANT®. Please read full [Prescribing Information](#) for LAZCLUZE™.

Results From a Clinical Trial

RYBREVANT® + LAZCLUZE™ is the only chemotherapy-free treatment proven to reduce the risk of cancer growing or spreading by 30% compared with the current standard of care (osimertinib)*



At 23.7 months, half of the people receiving RYBREVANT® + LAZCLUZE™ lived without their cancer growing or spreading, compared with 16.6 months for osimertinib.

In a clinical trial, 858 people with advanced NSCLC with common EGFR mutations received a first treatment of RYBREVANT® in combination with LAZCLUZE™ or a first treatment of osimertinib alone.


*Osimertinib is a preferred first treatment option for EGFR exon 19 deletion or exon 21 L858R mutations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 19, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

IMPORTANT SAFETY INFORMATION (cont’d)

How should I take LAZCLUZE™?

- Take LAZCLUZE™ exactly as your healthcare provider tells you to take it.
- Take LAZCLUZE™ one (1) time each day. On the day RYBREVANT® is also given, take LAZCLUZE™ any time before receiving the RYBREVANT® infusion.
- You can take LAZCLUZE™ with or without food.
- Swallow LAZCLUZE™ tablets whole. **Do not** crush, cut, or chew the tablets.
- If you miss a dose of LAZCLUZE™ and:
 - it has been **less than** 12 hours, take the missed dose.
 - it has been **more than** 12 hours, skip the dose and take your next dose at your regularly scheduled time.
- If you vomit a dose of LAZCLUZE™, do not take an extra dose. Take your next dose at your regularly scheduled time.
- LAZCLUZE™ may be given in combination with other anti-cancer medicines. If you have any questions about these medicines, ask your healthcare provider.

78% of people responded (tumors got smaller† or disappeared‡) with RYBREVANT® + LAZCLUZE™



Time that people responded (tumors got smaller† or disappeared‡)

Of people who responded, half were still responding at 25.8 months with RYBREVANT® + LAZCLUZE™ and 16.7 months with osimertinib.



†Tumors getting smaller may also be called a partial response. This means the tumor got measurably smaller but is still detectable.
‡Tumors disappearing may also be called a complete response. This does not necessarily mean the cancer has been cured.

Ask your doctor about the clinical results with RYBREVANT® + LAZCLUZE™

What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?

RYBREVANT® and RYBREVANT® in combination with LAZCLUZE™ can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT® and/or LAZCLUZE™. Wear protective clothing and use sunscreen during treatment with RYBREVANT® and/or LAZCLUZE™.

Please read Important Safety Information throughout and on pages 14-17.

6 Please read full [Prescribing Information](#) for RYBREVANT®. Please read full [Prescribing Information](#) for LAZCLUZE™.

Side Effects

Treatment may come with side effects, but they can be prevented or managed if you and your care team know what to expect and work together to manage them. Your care team may call these side effects or adverse reactions.

It's important to tell your care team about side effects right away, if you:

- First experience symptoms of side effects
- Feel that the side effects are affecting your daily activities
- Have been treating side effects according to your doctor's instructions but they do not improve

Your experience may vary. If you experience any of the following, tell your doctor right away.

Possible serious side effects of RYBREVANT® + LAZCLUZE™ include:



Infusion-related reactions (IRRs)

Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your doctor right away if you experience infusion-related reactions (shortness of breath, fever, chills, nausea, flushing, chest discomfort, lightheadedness, vomiting), with most occurring during the first infusion. Your treatment team may adjust or pause your infusion dosing and timing to help manage any reactions that may occur.



Lung problems

You may experience lung problems that may lead to death. Signs and symptoms of lung problems may be similar to those of lung cancer. Some of the common signs to watch out for are shortness of breath, cough, or fever. Tell your doctor right away if you have any new or worsening lung problems.



Blood clot problems ("venous thromboembolism" or "VTE")

Blood clots are a serious, but common side effect. You may experience blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Tell your doctor right away if you notice swelling, pain, or tenderness in the leg; sudden unexplained chest pain; or shortness of breath. Your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment.



Skin problems

You may experience severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Tell your doctor right away if you have any skin reactions. They may treat you with medicine(s) or send you to see a skin specialist (dermatologist). It may be helpful to proactively take steps to minimize any discomfort. Please read the "Tips for Managing Side Effects" on the next page for proactive steps you can take.



Eye problems

You may experience eye problems, which may include eye pain, inflammation of eyelids, inflamed cornea (front part of the eye), dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. Your doctor may refer you to an eye specialist (ophthalmologist). You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

Harm to your unborn baby

RYBREVANT® and LAZCLUZE™ can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. If you are able to become pregnant you should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT® and during treatment and for 3 weeks after your last dose of LAZCLUZE™. Tell your doctor right away if you become pregnant or think you might be pregnant. If your partner is able to become pregnant you should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.

Most common side effects of RYBREVANT® + LAZCLUZE™:

- | | | | |
|---|--|----------------|----------------------------------|
| • Rash | • Swelling of hands, ankles, feet, face, or all of your body | • Diarrhea | • Decreased appetite |
| • Infected skin around the nail | | • Constipation | • Itchy skin |
| • Infusion-related reaction (amivantamab) | • Unusual feeling in the skin (such as tingling or crawling feeling) | • COVID-19 | • Nausea |
| • Muscle and joint pain | • Feeling very tired | • Dry skin | • Changes in certain blood tests |
| • Sores in the mouth | | • Bleeding | |

Your care team can help prevent or manage side effects and help you stay on treatment.

Please read Important Safety Information throughout and on pages 14-17.

8 Please read full Prescribing Information for RYBREVANT®. Please read full Prescribing Information for LAZCLUZE™.

Tips to Help Manage Side Effects

It's important to work with your care team before treatment to help lower the risk of side effects

Members of your care team, including your dermatologist, nurse, nurse practitioner, pharmacist, and physician assistant can help. Pausing, decreasing the dose, or stopping treatment may be needed in some cases to help manage side effects.

Here are some useful tips:



Clothing

- Wear loose-fitting and soft clothes
- Consider wearing soft clothes underneath any scratchy fabrics (such as wool)
- Use laundry detergents made for sensitive skin and without perfumes



Hygiene

- Use alcohol-free (such as isopropanol-free, ethanol-free) moisturizing cream
- Consider bathing/showering with warm or cool water (not hot water)
- Use mild soaps and shampoos, such as those for sensitive skin



Environment

- Limit sun exposure during and for 2 months after treatment
- Wear protective clothing and use sunscreen
- Wear gloves during activities that could cause nail infections (such as cleaning)
- Use a humidifier if in a dry environment



Medicines to discuss with your care team

- Steroids and antibiotics to help prevent or reduce skin problems
- Allergy medicines, steroids, and fever reducers to help prevent or reduce infusion-related reactions
- Blood thinners to help prevent or reduce the risk of blood clots

Talk to your care team to understand if these tips are right for you.



Always tell your care team if you experience side effects, so you can help manage them together.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of RYBREVANT® or LAZCLUZE™?

RYBREVANT® and LAZCLUZE™ may cause serious side effects, including:

- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:
 - o shortness of breath
 - o fever
 - o chills
 - o nausea
 - o flushing
 - o chest discomfort
 - o lightheadedness
 - o vomiting



How RYBREVANT® + LAZCLUZE™ Are Given

RYBREVANT® is an infusion given into your vein through an IV (intravenous) line.
LAZCLUZE™ is a pill taken once a day at home and on your own schedule.

- You'll be given RYBREVANT® infusions at your doctor's office or an infusion center.
- Your doctor will decide how many infusions you will receive, the time between infusions, and the appropriate amount of medicine in each infusion (based on your body weight).
- Your doctor will also give you other medicines before infusions to help reduce the risk of side effects, such as allergy medicine, a fever reducer, and a steroid.
- Your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment.
- On days when you are receiving RYBREVANT®, take your LAZCLUZE™ pill before receiving your RYBREVANT® infusion.

RYBREVANT® infusion schedule recommendation

Your first dose Week 1 (Day 1 & Day 2)



- Your first dose will be split across 2 days
- Your first dose can take about 4 to 8 hours
- Your dose may be adjusted to help manage possible side effects

Your next 4 doses Weeks 2-5



- After your first week, you'll get 1 infusion each week for the next 4 weeks
- Infusions can get shorter

Additional doses Every 2 weeks (starting on Week 7)



- Starting on Week 7, you'll get 1 infusion every 2 weeks
- Subsequent infusion time is approximately 2 hours

If you have any other questions about your treatment, ask your care team.

LAZCLUZE™ is a once-a-day pill



You can take at home or wherever is convenient



On your own schedule



With or without food

LAZCLUZE™ is a 240mg once-a-day pill. Swallow LAZCLUZE™ pills whole. Do not crush, cut, or chew the pills.

- If you miss a pill, and it has been less than 12 hours, take the missed pill. If it has been more than 12 hours, skip the pill and take your next pill at your regularly scheduled time.
- If you vomit a dose of LAZCLUZE™, do not take an extra dose. Take your next dose at your regularly scheduled time.
- Take LAZCLUZE™ exactly as your doctor tells you to take it.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of RYBREVANT® or LAZCLUZE™? (cont'd)

- **lung problems.** RYBREVANT® may cause lung problems that may lead to death. LAZCLUZE™ may also cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** Blood clots are a serious, but common side effect of RYBREVANT®, when given together with LAZCLUZE™, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT® can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. LAZCLUZE™ may cause severe rash including redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT® or LAZCLUZE™. See "What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?"

Please read Important Safety Information throughout and on pages 14-17.

10 Please read full [Prescribing Information](#) for RYBREVANT®. Please read full [Prescribing Information](#) for LAZCLUZE™.

Tips to help you prepare for your infusion appointments



Drink plenty of water the day before your infusion and have a healthy breakfast the morning of the infusion.



Wearing loose clothing can help keep you comfortable in the infusion room and allow your care team to easily access the infusion area of your body.



Infusions can last several hours, so make sure you've set aside enough time for your appointment. Ask your care team about how long your infusion will be.



Bring a pillow and blanket for extra comfort.



Bring a drink and snack with you to your appointment in case you get hungry, but check with the office first.



Bring a book, game, puzzle, music, or other entertainment to help pass the time.



Consider setting up transportation to and from the infusion center. You may receive medicines before your infusion that can make you drowsy. If you need help setting up a ride, reach out to your family and friends.



Pay close attention to how you feel during an infusion, and make sure you let your care team know if you experience any discomfort. They know how to help.



Your care team may give you allergy medicine, a fever reducer, or a steroid to help reduce the risks of serious side effects from the infusion.

Talk to your care team about how to best prepare for your infusion appointments.

Support & Savings

Once you and your doctor have decided that RYBREVANT® is right for you, sign up for RYBREVANT withMe support

RYBREVANT withMe

You have access to free, dedicated support. Your Care Navigator is here to help guide you to support solutions throughout your treatment journey, so you feel informed and empowered

Free 1-on-1, Dedicated Support



Free 1-on-1
Dedicated Care
Navigator Support



Cost Support
Options Regardless
of Your Insurance
Type



Additional
Resources
and Community
Connections

Get a free Patient Starter Kit with educational resources for your RYBREVANT® treatment journey. A Care Navigator can help you learn more about what is included and send you one.



Sign up for personalized support throughout your treatment journey now by visiting RYBREVANTWithMe.com, or calling 833-JNJ-wMe1 (833-565-9631), Monday through Friday, 8:00 AM–8:00 PM ET.

Message and data rates may apply.

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

*Care Navigators do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment.

Please read Important Safety Information throughout and on pages 14-17.

12 Please read full [Prescribing Information](#) for RYBREVANT®. Please read full [Prescribing Information](#) for LAZCLUZE™.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE™ (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™ is right for you.

It is not known if RYBREVANT® or LAZCLUZE™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT® as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT® and LAZCLUZE™ can harm your unborn baby.

Females who are able to become pregnant:

- o Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™.
- o You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
- o For patients receiving LAZCLUZE™: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- o Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT® or LAZCLUZE™.

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT®. It is not known if LAZCLUZE™ passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE™.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE™ may affect the way other medicines work, and other medicines may affect how LAZCLUZE™ works.

You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE™.

How will I receive RYBREVANT®?

- RYBREVANT® will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of infusion-related reactions.

- RYBREVANT® may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
- If your treatment with RYBREVANT® is given in combination with LAZCLUZE™ (lazertinib), you should take your dose of LAZCLUZE™ by mouth anytime before your infusion with RYBREVANT®.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

How should I take LAZCLUZE™?

- Take LAZCLUZE™ exactly as your healthcare provider tells you to take it.
- Take LAZCLUZE™ one (1) time each day. On the day RYBREVANT® is also given, take LAZCLUZE™ any time before receiving the RYBREVANT® infusion.
- You can take LAZCLUZE™ with or without food.
- Swallow LAZCLUZE™ tablets whole. Do not crush, cut, or chew the tablets.
- If you miss a dose of LAZCLUZE™ and:
 - o it has been less than 12 hours, take the missed dose.
 - o it has been more than 12 hours, skip the dose and take your next dose at your regularly scheduled time.
- If you vomit a dose of LAZCLUZE™, do not take an extra dose. Take your next dose at your regularly scheduled time.
- LAZCLUZE™ may be given in combination with other anti-cancer medicines. If you have any questions about these medicines, ask your healthcare provider.

What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?

RYBREVANT® and RYBREVANT® in combination with LAZCLUZE™ can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT® and/or LAZCLUZE™. Wear protective clothing and use sunscreen during treatment with RYBREVANT® and/or LAZCLUZE™.

What are the possible side effects of RYBREVANT® or LAZCLUZE™?

RYBREVANT® and LAZCLUZE™ may cause serious side effects, including:

- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:

o shortness of breath	o flushing
o fever	o chest discomfort
o chills	o lightheadedness
o nausea	o vomiting
- **lung problems.** RYBREVANT® may cause lung problems that may lead to death. LAZCLUZE™ may also cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** Blood clots are a serious, but common side effect of RYBREVANT®, when given together with LAZCLUZE™, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.

INDICATIONS AND IMPORTANT SAFETY INFORMATION (cont'd)

- **skin problems.** RYBREVANT® can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. LAZCLUZE™ may cause severe rash including redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT® or LAZCLUZE™. See “What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?”
- **eye problems.** RYBREVANT® may cause eye problems. LAZCLUZE™ may also cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
 - o eye pain
 - o inflammation of eye lids
 - o inflamed cornea (front part of the eye)
 - o dry eyes
 - o eye redness
 - o blurred vision
 - o changes in vision
 - o itchy eyes
 - o excessive tearing
 - o sensitivity to light
 - o new or worsening problems with vision

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT® or LAZCLUZE™. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT® in combination with LAZCLUZE™ (lazertinib) include:

- rash
- infected skin around the nail
- muscle and joint pain
- sores in the mouth
- swelling of hands, ankles, feet, face, or all of your body
- unusual feeling in the skin (such as tingling or a crawling feeling)
- feeling very tired
- diarrhea
- constipation
- COVID-19
- dry skin
- bleeding
- decreased appetite
- itchy skin
- nausea
- changes in certain blood tests

The most common side effects of RYBREVANT® in combination with carboplatin and pemetrexed include:

- rash
- infected skin around the nail
- sores in the mouth
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- constipation
- decreased appetite
- nausea
- COVID-19
- diarrhea
- vomiting
- changes in certain blood tests

The most common side effects of RYBREVANT® when given alone:

- rash
- infected skin around the nail
- muscle and joint pain
- shortness of breath
- nausea
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- sores in the mouth
- cough
- constipation
- vomiting
- changes in certain blood tests

LAZCLUZE™ may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® or LAZCLUZE™ if you have serious side effects.

These are not all of the possible side effects of RYBREVANT® or LAZCLUZE™.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your healthcare provider or pharmacist for information about RYBREVANT® that is written for health professionals.

General information about the safe and effective use of LAZCLUZE™:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LAZCLUZE™ for a condition for which it was not prescribed. Do not give LAZCLUZE™ to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about LAZCLUZE™ that is written for health professionals.

Please read full [Prescribing Information](#) for RYBREVANT®.

Please read full [Prescribing Information](#) for LAZCLUZE™.

cp-213277v5



Facing lung cancer together

You're not alone. There are many groups available to help people facing cancer and their loved ones.



BeLUNG Here

Visit belunghere.org



EGFR Resisters

Visit egfrcancer.org



GO2 Foundation for Lung Cancer

Visit go2.org



The International Association for the Study of Lung Cancer (IASLC)

Visit iaslc.org



Lung Cancer Foundation of America (LCFA)

Visit lcfamerica.org



LUNGevity

Visit lungevity.org

Learn more about treatment and **sign up to receive a Patient Starter Kit** at RYBREVANTwithMe.com.